A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Patients are randomized to receive either hard gel or soft gel capsules of saquinavir in combination with at least one licensed nucleoside antiretroviral. Treatment will continue for 48 weeks. After the first 16 weeks, patients will be given the opportunity to roll over to the saquinavir formulation of choice.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
13 Years and older (Child, Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients must have:
Antiretroviral naiveness (i.e., less than 4 weeks of prior treatment) to at least one of the licensed nucleoside drugs.
No more than 2 weeks of prior treatment with a protease inhibitor.
No active opportunistic infection or other serious AIDS-defining condition.
Patients with the following symptoms or conditions are excluded:
Malabsorption or inadequate oral intake.
Lab or clinical abnormality worse than grade 3 (other than exercise-induced CPK elevations).
Unexplained, chronic diarrhea, defined as more than three loose stools per day persisting for 2 weeks or more within the month prior to study entry.
Active malignancy or anticipated need for chemotherapy during the study.
Anticipated need for disallowed medications during the study.
Other protease inhibitors.
More than 4 weeks of the prior nucleoside antiretroviral selected for the patient's regimen.
Thompson M. Activity of soft gelatin capsule formulation of saquinavir in combination with two nucleosides in treatment-naive HIV-1-seropositive persons. The NV15355 Study Team. Int Conf AIDS. 1998;12:40 (abstract no 12145)